Peptone
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Peptone firmographics
Firmographics- Name
- Peptone
- Legal name
- Peptone Ltd.
- Website
- https://peptone.io
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Peptone industry classification
Industry- Product category
- AI-Driven Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Peptone is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Peptone business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Therapeutic Development and Licensing: Peptone is a pre-revenue biotech company developing novel first-in-class small molecule therapeutics targeting intrinsically disordered proteins (IDPs). Revenue will be generated through licensing deals with pharmaceutical partners, co-development agreements, and ultimately drug commercialization.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Peptone product offering
Product offeringCore offering
Peptone develops first-in-class small-molecule therapeutics targeting intrinsically disordered proteins (IDPs), a class representing more than 30% of the human proteome that traditional structure-based drug discovery cannot address. Its central offering is the Oppenheimer product engine, which integrates bespoke HDX mass spectrometry, NVIDIA GPU-accelerated molecular modeling, and generative AI to go from validated IDP pockets to characterized small-molecule binders in weeks.
Product overview
Peptone is a biotechnology company developing novel small-molecule therapeutics targeting intrinsically disordered proteins (IDPs). Its product portfolio is anchored by the Oppenheimer product engine — a unified platform combining bespoke mass spectrometry (Unique Mass Spectrometry System), GPU-accelerated protein modeling (D-TRON and PEP-TRON), generative AI-driven small-molecule design, and a BSL-2 laboratory for assay development and efficacy testing. The Oppenheimer engine processes experimental HDX-MS data through AI and molecular dynamics to generate and characterize binders at a throughput of 2 billion per week. Key offerings also include PepTron-o (jointly developed with NVIDIA on BioNeMo), which provides ensemble-first structure prediction for the disordered proteome with a universal reweighting framework.
Differentiator
Problem solved
Functional benefit
Brands
- Oppenheimer: Peptone's product engine that combines physics, molecular biology and next-generation supercomputing for small molecule design for intrinsically disordered proteins. Features pocket detection, novel structural insights, experimental structure generation, AI-driven binder design, and binder characterization capabilities.
Products and services
- Oppenheimer Peptone's focal product engine integrating physics, molecular biology, and next-generation supercomputing for small-molecule drug design targeting intrinsically disordered proteins. Encompasses pocket detection via bespoke HDX mass spectrometry, AI-driven binder design at 2 billion binders per week throughput, and experimental structure generation combining generative AI and molecular dynamics. Used internally by Peptone and offered to pharmaceutical partners for IDP-targeted therapeutic co-development.
- PepTron-o An ensemble-first structure prediction model for the disordered proteome developed jointly with NVIDIA and built on the BioNeMo platform. Provides automated conformational diversity prediction for intrinsically disordered regions together with a universal reweighting framework that evaluates each structure in an ensemble against high-quality NMR observables and back-propagates corrections. Designed to be model-agnostic and droppable on top of any ensemble generator to improve precision.
- Assay Development and Efficacy Testing Services End-to-end wet lab service offering including target expression, characterization, assay development, and biological efficacy testing, conducted in Peptone's 8,000-square-foot BSL-2 laboratory in Bellinzona, Switzerland. Available to support Peptone's internal programs and pharmaceutical partner co-development engagements.
Quantifiable outcome
- Concept to chemical matter in weeks
- +2 more outcomes
Companies that use Peptone
Customer profileSegments1 record
Ideal customer profiles1 record
Peptone technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature5 records
Peptone partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, supporting and minor.
- NVIDIAcoreCollaboration with NVIDIA to develop PepTron-o, the Ensemble First Structure Prediction model for the disordered proteome. Based on NVIDIA BioNeMo platform, utilizing fused attention kernels, mixed-precision arithmetic, and GPU parallelism for protein structure generation. Joint presentation at GTC Paris 2025 and VivaTech 2025.
- EvoteccoreStrategic partnership combining Peptone's pioneering physics-based HDX-MS platform for identifying novel IDP pockets with Evotec's extensive drug discovery toolbox including deep assay expertise, medicinal chemistry, and state-of-the-art screening capabilities. The collaboration aims to accelerate and scale small molecule therapeutics targeting IDPs across diverse therapeutic areas.
- Amazon Web Services (AWS)supportingPeptone's ultra-scalable computing and data processing architecture is powered by Kubernetes and Amazon Web Services (AWS). This architecture handles complex computational demands of protein structure prediction, leveraging both model and data parallelism to efficiently sample conformational spaces across GPU nodes.
- ELIXIR CZ ConsortiumminorPeptone CEO Dr. Kamil Tamiola joined the Scientific Advisory Board of ELIXIR CZ, the Czech National Infrastructure for Biological Data. ELIXIR CZ coordinates European life science resources and focuses on organizing, storing, and sharing biological data for research analysis.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Peptone competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-enabled drug discovery company using high-throughput experimental data and foundation models to identify novel therapeutics; comparable to Peptone in combining proprietary wet-lab data generation with ML/AI for novel target identification and small-molecule design.
- Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning for hit identification; comparable to Peptone in applying AI/ML to small-molecule design across difficult target classes.
- BenevolentAI: AI drug discovery company combining knowledge graphs with ML to identify new drug targets and indications; comparable to Peptone as a fellow AI-platform biotech pursuing difficult targets with computational methods.
- Schrödinger: Computational chemistry and materials science platform company using physics-based simulation and ML for drug discovery; directly comparable to Peptone's use of GPU-accelerated molecular dynamics, physics-based modeling, and AI for small-molecule design.
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to discover therapeutics; directly comparable to Peptone's platform approach of integrating bespoke experimental data with AI models to generate novel drug candidates against difficult targets.
- Relay Therapeutics: Precision medicine company using motion-based protein design and computational chemistry to discover allosteric small-molecule inhibitors; comparable to Peptone in leveraging dynamic protein behavior (vs. static structures) for novel druggable pocket identification.
- Exscientia: AI-driven pharma company using generative AI for small-molecule drug design (now combined with Recursion); directly comparable to Peptone in applying generative AI and automated chemistry to accelerate discovery of novel therapeutics.
- Isomorphic Labs: Alphabet-founded AI drug discovery company spun out of DeepMind's AlphaFold work; comparable to Peptone in leveraging AI/protein structure prediction for novel therapeutic target identification, though focused on broader structural biology rather than IDPs specifically.
Emerging players
- Neumora Therapeutics: AI-driven neuroscience drug discovery company combining data science with neurobiology for CNS therapeutics; comparable to Peptone in using AI platforms to address historically undruggable targets with novel chemistry.
- Generate Biomedicines: Generative AI biology company designing novel protein therapeutics computationally; partially comparable to Peptone in applying generative AI to protein/therapeutic design, though focused on biologics rather than small molecules.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Peptone social profiles
Digital presencePeptone financial estimates
Financial estimateRevenue estimate
Valuation estimate
Peptone leadership team
Management profileNumber of profiles
Profiles11 records
Peptone funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Peptone M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Peptone
What does Peptone do?
Peptone develops first-in-class small-molecule therapeutics targeting intrinsically disordered proteins (IDPs), a class representing more than 30% of the human proteome that traditional structure-based drug discovery cannot address. Its central offering is the Oppenheimer product engine, which integrates bespoke HDX mass spectrometry, NVIDIA GPU-accelerated molecular modeling, and generative AI to go from validated IDP pockets to characterized small-molecule binders in weeks.
Is Peptone a public or private company?
Peptone is a private company. It is classified as venture growth investor backed and is currently operating.
When was Peptone founded?
Peptone was founded in 2018. It employs 11 to 50 people.
Where is Peptone based?
Peptone is headquartered in London, United Kingdom, in the Europe region.
How does Peptone make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are Peptone's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Atomwise, BenevolentAI, Schrödinger, Insitro, Relay Therapeutics, Exscientia and Isomorphic Labs. Emerging players are Neumora Therapeutics and Generate Biomedicines.
Does Peptone have an API?
No public API is recorded for Peptone.
What industry is Peptone in?
Peptone's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.